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Aims We tested the hypothesis that atrioventricular (AV) junction ablation in conjunction biventricular pacing [cardiac
resynchronization (CRT)] pacing is superior to pharmacological rate-control therapy in reducing heart failure (HF)
and hospitalization in patients with permanent atrial fibrillation (AF) and narrow QRS.
...................................................................................................................................................................................................
Methods
and results
We randomly assigned 102 patients (mean age 72 ± 10 years) with severely symptomatic permanent AF
(>6 months), narrow QRS (<_110 ms), and at least one hospitalization for HF in the previous year to AV junction
ablation and CRT (plus defibrillator according to guidelines) or to pharmacological rate-control therapy (plus defib-
rillator according to guidelines). After a median follow-up of 16 months, the primary composite outcome of death
due to HF, or hospitalization due to HF, or worsening HF had occurred in 10 patients (20%) in the AblationþCRT
arm and in 20 patients (38%) in the Drug arm [hazard ratio (HR) 0.38; 95% confidence interval (CI) 0.18–0.81;
P= 0.013]. Significantly fewer patients in the AblationþCRT arm died from any cause or underwent hospitalization
for HF [6 (12%) vs. 17 (33%); HR 0.28; 95% CI 0.11–0.72; P= 0.008], or were hospitalized for HF [5 (10%) vs. 13
(25%); HR 0.30; 95% CI 0.11–0.78; P= 0.024]. In comparison with the Drug arm, AblationþCRT patients showed a
36% decrease in the specific symptoms and physical limitations of AF at 1 year follow-up (P= 0.004).
...................................................................................................................................................................................................
Conclusion AblationþCRT was superior to pharmacological therapy in reducing HF and hospitalization and improving quality
of life in elderly patients with permanent AF and narrow QRS.
...................................................................................................................................................................................................
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Introduction
There is sufficient evidence of the efficacy of atrioventricular (AV)
junction ablation plus right ventricular (RV) pacing in improving the
symptoms of high heart rate and exercise tolerance in patients with
atrial fibrillation (AF). By contrast, most studies and meta-analyses
have yielded neutral results regarding the progression of heart failure
(HF), hospitalization, and mortality,1–11 with one exception.12
The downside is that, in patients with native narrow QRS, the non-
physiological RV pacing is reported to induce left ventricular (LV)
dyssynchrony in about 50% of cases,13,14 which may be followed by
symptoms of worsening of HF. Indeed, on RV pacing, the ventricular
activation sequence resembles that of left bundle branch block, i.e.
the LV septum is activated before the LV free wall. Cardiac resynch-
ronization therapy (CRT) may prevent the potential LV dyssyn-
chrony induced by RV pacing and therefore appears to be an
interesting approach in patients eligible for AV junction ablation.
While there is a rationale for an additive effect of CRT to that of
AV junction ablation, the benefit of this strategy, in comparison with
that of pharmacological rate-control therapy, has never been studied
in trials of patients with permanent AF and native narrow QRS.
Narrow QRS (i.e. <120 ms) is a contraindication for CRT in patient
with sinus rhythm.15–17
What we know from the literature is that CRT is better than RV
pacing, after AV junction ablation, in heterogeneous AF populations,
which have mainly included HF patients with wide QRS and
depressed systolic function.18–22 Post hoc analyses of small subpopula-
tions have been unable to find differences in outcome between
patients with narrow QRS and those with wide QRS, nor between
patients with depressed ejection fraction (EF) and those with pre-
served EF, thus suggesting a similar benefit.19,22 However, given the
lack of a control group of patients without AV junction ablation, CRT
could have simply counteracted the harmful effect of RV pacing with-
out affecting the global outcome.
The need to compare pharmacological and non-pharmacological
rate-control strategies constituted the rationale of the Ablate and
Pace in Atrial Fibrillation plus Cardiac Resynchronization Therapy
(APAF-CRT) trial. The purpose of the APAF-CRT trial was to dem-
onstrate the superiority of an approach consisting of AV junction ab-
lation and CRT pacing over optimal pharmacological rate control in
patients with permanent AF and narrow QRS regarding the progres-
sion of HF, hospitalization and mortality.
Methods
The APAF-CRT trial was a prospective, randomized, parallel, open-label
clinical trial involving patients with severely symptomatic permanent AF
and narrow QRS, and consisted of two specific consecutive (overlapping)
phases, i.e. a morbidity trial and a mortality trial. The morbidity trial, which
was conducted in 10 European general hospitals, was designed to test the
hypothesis that AV junction ablation and biventricular pacing is superior
to pharmacological rate-control therapy in reducing HF and hospitaliza-
tion. Recruitment began in October 2014 and patients were followed up
for a maximum period of 3 years, during which yearly visits were
required. Additionally, symptomatic status was assessed at 1 year. Events
were collected by investigators by means of a web-based electronic sys-
tem and were finally adjudicated by an independent Clinical Events
Committee, the members of which were blind to therapy assignment.
The study protocol was approved by the local ethics committee at each
participating institution and complied with the provisions of the
Declaration of Helsinki. Written informed consent was obtained from all
patients.
Patients
Patient inclusion criteria were as follows: (i) severely symptomatic per-
manent AF (>6 months) which has been considered unsuitable for AF ab-
lation or in which AF ablation had failed; (ii) narrow QRS (i.e. <_110 ms);
and (iii) at least one hospitalization for HF in the previous year.
Patient exclusion criteria were as follows: (i) hospital New York Heart
Association (NYHA) Class IV and systolic blood pressure <_80 mmHg
despite optimized therapy; (ii) severe concomitant non-cardiac disease;
(iii) need for surgical intervention; (iv) myocardial infarction within the
previous 3 months; (v) previously implanted devices.
Randomization and procedures
Patients were randomized in a 1:1 ratio to AV junction ablation and
biventricular pacing (plus defibrillator according to guidelines) (Ablation
and CRT arm) or optimal pharmacological rate-control therapy (plus de-
fibrillator according to guidelines) (Drug arm). A randomly permuted-
block randomization list was generated by computer at a central location
and was stratified by centre and by baseline EF (<_35% and >35%).
Any commercially available CRT-P or CRT-D device was permitted.
The RV lead was positioned in the RV apex. The LV lead was targeted to
the basal-mid-portions of the free wall. The atrial port of the device was
excluded. The final programming of the implanted device was left to the
physicians’ discretion. Defibrillator back-up was chosen at the discretion
of the physicians according to the guidelines of the European Society of
Cardiology (ESC).15 System revision was recommended during all follow-
up visits if persistent capture was not obtained.
In the ablation arm, right-sided AV junction ablation was attempted
first; the left approach was added if right-sided ablation failed to achieve
persistent third-degree AV block. Repeated ablation procedures were
recommended during follow-up if regression of AV block had occurred.
Cardiac resynchronization therapy device implantation and ablation
procedures were performed as soon as possible after randomization and
within a maximum time of 30 days. Pharmacological HF therapy was opti-
mized according to current guidelines in both arms. In the control arm,
the rate-control therapy was optimized in order to achieve a resting heart
rate <110 b.p.m.23
Outcomes
The primary outcome was a composite of death due to HF, or hospital-
ization due to HF, or worsening HF, whichever occurred first. Secondary
clinical outcomes were total mortality, hospitalization for HF, and wor-
sening HF. Hospitalization for HF was defined as a hospital admission that
was associated with an overnight stay owing to the occurrence of increas-
ing symptoms of congestive HF which necessitated a substantial increase
in diuretics and/or appropriate treatment for uncontrolled intolerable
AF-related symptoms. Worsening HF was defined as a worsening of signs
and symptoms of congestive HF, i.e. documentation of worsening symp-
toms of shortness of breath at rest and during effort, effort intolerance or
easy fatigue, and of objective signs of HF, which included data regarding
volume retention, pulmonary rales and the need for adjunctive therapy,
and/or the need for appropriate treatment for uncontrolled intolerable
AF-related symptoms. Death due to HF was defined as death occurring in
the context of clinically worsening symptoms and/or signs of HF without
evidence of another cause of death.
The primary and secondary clinical outcomes were adjudicated by a
Clinical Events Committee, whose members were unaware of the
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patients’ study-group assignments. The primary and secondary clinical
outcomes were analysed according to the intention-to-treat (ITT)
principle.
The tertiary outcome was quality of life, which was assessed at the
baseline and during the 1 year follow-up visit. Quality of life was assessed
by means of the European Heart Rhythm Association (EHRA) score23
and the six-item Specific Symptom Scale (SSS) score. The physician-
administered four-item EHRA score classifies AF symptoms as absent,
mild, severe, or disabling.23 The self-administered SSS was developed as a
disease-specific instrument to measure the patient’s perception of the
frequency and severity of arrhythmia-related symptoms. This instrument
has been demonstrated to discern changes in the symptoms of patients
with AF, both in sequential and in case–control studies.2,24 An on-
treatment analysis was applied to quality of life scores.
Statistical analysis
Data analysis
In all analyses, we used a two-sided Type-1 error alpha = 0.05.
Continuous data are shown as means ± standard deviation or medians
(25th–75th percentile), as appropriate. Absolute and relative frequencies
were used to compare categorical data. A paired Student’s t-test was
used to compare continuous variables, Fisher’s exact test was used to
compare proportions, and analysis of variance for repeated measures
was used to compare treatment effect and EF effect within subjects. The
Greenhouse-Geisser adjustment was applied to degrees of freedom, and
equal weights were attributed to measurements. Patients who did not
suffer a pre-specified event were censored at the last observation. For
the ITT analysis of, the primary and secondary outcomes, the hazard ratio
(HR) of treatment allocations were estimated by means of Cox’s propor-
tional hazard regression model, after checking for the assumption of pro-
portionality. In addition, the primary and secondary outcomes were
described by means of the Kaplan-Meier product-limit method and com-
pared by means of the log-rank test. Sensitivity analyses were also per-
formed. Analyses were performed by means of MedCalc version 15.8
(MedCalc Software, Mariakerke, Belgium) and IBM SPSS v.24 (IBM
Software Group, Chicago, IL, USA).
Sample size justification
In the APAF trial,22 26% of patients in the control RV pacing arm reached
the same combined Endpoint as that of this study at 12 months; CRT
reduced this rate by 63%. Thus, in a prudential estimation which assumed
that morbidity on drug therapy would be equal to that of RV pacing, 137
patients in each group would have 80% power to detect a 60% relative
reduction in the primary composite outcome after a maximum follow-up
of 3 years (accrual of 2 years) with a two-sided alpha of 5% and a common
exponential dropout rate of 10%.
Interim analysis
In absence of historical data regarding the benefit of CRT pacing vs. rate-
control drug therapy that could allow a more realistic sample size calcula-
tion, we planned an ad-interim analysis once 50% of the statistical infor-
mation had been obtained. This was assumed to occur at 50% of patients,
figure which is equivalent to 25 adjudicated primary outcome events. On
8 May 2018, following the interim analysis, the Clinical Events Committee
informed the principal investigator that the difference observed between
the two arms was very close to that specified in the ‘stopping rule, recom-
mended that the trial be terminated on account of the evident superiority
of the results obtained in one of the arms, and selected 23 June 2018, as
the cut-off date for all efficacy analyses; the sponsor accepted this deci-
sion. As per protocol, the investigators were informed that the study
would continue after that date, in order to evaluate the mortality out-
come (i.e. APAF Mortality trial).
Results
Patients
A total of 109 patients were randomized; 102 of these were finally
included for analysis and assigned to the Ablation and CRT arm (50
patients) or to the Drug arm (52 patients) (Figure 1). The two study
groups were generally well matched with respect to baseline charac-
teristics (Table 1). After the optimization period, fewer patients
assigned to Ablation and CRT received digoxin (P= 0.03) and vasodi-
lators (P= 0.26) during the study period than those assigned to the
Drug arm; more patients assigned to Ablation and CRT received
angiotensin-converting enzyme inhibitors or receptor blocker during
the study period than those assigned to the Drug arm (P= 0.16). In
the Ablation and CRT arm, the median time from randomization to
CRT implantation was 2.5 days (interquartile range 1–8). The median
time from randomization to AV junction ablation was 6 days (inter-
quartile range 2–21). In four patients, ablation failed to achieve a per-
sistent AV block; they were analysed in the Ablation and CRT arm
according to the intention-to treat principle for primary and second-
ary endpoints and in the Drug arm according to the on-treatment
principle for tertiary endpoint. Another three patients, who had a sta-
ble AV block after AV junction ablation but underwent only RV pac-
ing, owing to the failure of coronary sinus pacing, were analysed in
the Ablation and CRT arm with regard to all endpoints. A defibrillator
back-up was given to 22 patients in the Ablation and CRT arm (i.e. a
CRT-D device) and to 20 patients in the Drug arm (i.e. an ICD de-
vice). During follow-up, a total of 12 patients assigned to the Drug
arm, crossed-over to AV junction ablation and CRT after a median of
135 days (interquartile range 58–207).
Outcome
The median duration of follow-up was 16 months, with no significant
difference between groups.
On ITT analysis, at the time of study closure, the primary compos-
ite outcome of death due to HF, or hospitalization due to HF, or
worsening HF had occurred in 10 patients (20%) in the
AblationþCRT arm and in 20 patients (38%) in the Drug arm [HR in
the AblationþCRT arm, 0.38; 95% confidence interval (CI) 0.18–
0.81; P= 0.013] (Table 2 and Take home figure). No heterogeneity
among centres was found: P= 0.29. The HR was 0.18 (95% CI 0.05–
0.66; P= 0.010) in the 43 patients who had an EF <_35%, and 0.62
(95% CI 0.23–1.70; P= 0.359) in the 59 patients who had an EF >35%
(Supplementary material online, Figure S1). A total of 6 patients (12%)
receiving AblationþCRT and 17 patients (33%) receiving drugs died
from any cause or underwent hospitalization for HF (HR 0.28; 95%
CI 0.11–0.72; P= 0.008). A total of 2 patients (4%) receiving
AblationþCRT and 6 patients (12%) receiving drugs died from any
cause (HR 0.30; 95% CI 0.06–1.50; P= 0.147). Details of the cause of
death are provided in Supplementary material online, Table S1. A
total of 5 patients (10%) receiving AblationþCRT and 13 patients
(25%) receiving drugs underwent hospitalization for HF (HR 0.30;
95% CI 0.11–0.78); P= 0.024). A subgroup analysis of the primary
outcome is shown in Figure 2. The results of sensitivity analyses of the
AV junction ablation and CRT in AF patients 4001
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analysis (Supplementary material online, Figure S2).
Symptoms and physical limitations
Symptoms and physical limitations were assessed by means of on-
treatment analysis during the 1 year visit in the 92 patients who
attended for follow-up examination. The 50 patients who underwent
effective Ablation and CRT had a 36% lower total SSS score than the
42 patients on Drug therapy (10.5 ± 8.7 vs. 16.3 ± 11.2) and a greater
reduction from baseline (difference 19.1± 10.4 vs. 12.7± 11.2);
repeated measures ANOVA for treatment effect: F(1,90) = 8.60;
P= 0.0043 (Table 3). The EHRA score decreased from the baseline
by >_1 point in 76% of Ablation and CRT patients and in 43% of Drug
arm patients, P= 0.001. The greatest improvements in symptoms
were observed in Ablation and CRT patients with EF >35%,
P= 0.0003 (Figure 3), with a >_ 1 point reduction in EHRA score in
90% of cases (P= 0.0003). At the time of the 1 year visit, the patients
in the Ablation and CRT arm had a mean heart rate of 71 ± 5 b.p.m.
and a percentage of biventricular pacing of 98% ± 3%; two patients
were in sinus rhythm (þ AV block). The Drug arm patients had a
mean heart rate of 78 ± 15 b.p.m.; three were in sinus rhythm.
Adverse events
Two patients (1 Ablation and CRT and 1 Drug arm) had appropriate
ICD shocks for ventricular tachyarrhythmias after 10 and 5 months,
respectively. One patient (Ablation and CRT arm) underwent cath-
eter ablation for recurrent episodes of ventricular tachycardia. Five
patients (Drug arm) suffered inappropriate ICD shocks for AF with
high ventricular rate. Three patients had lead dislodgement which
required repositioning. Two patients (Drug arm) had acute
coronary syndrome. In two patients in the Ablation and CRT group
and one in the Drug group, a diagnosis of cancer was made after
randomization.
Discussion
Compared with pharmacological rate control, AV junction ablation
and CRT reduced the risks of death due to HF, or hospitalization
due to HF, or worsening HF by 62% and improved specific symptoms
of AF by 36% in elderly patients with permanent AF and narrow
QRS.
We hypothesizes that the observed benefit was due to the com-
bination of the almost perfect rate regularization achieved by AV
junction ablation and CRT pacing, which counteracted the adverse
effects of iatrogenic AV block induced by ablation. In the absence of
CRT, earlier studies and meta-analyses of AV junction ablation and
RV pacing1–11 were unable to find an improvement in HF, hospitaliza-
tion and survival in comparison with medical therapy; the improve-
ment in symptoms and quality of life was mostly related to
ventricular rate control rather than to improved cardiac function.
Ablate and Pace in Atrial Fibrillation plus Cardiac Resynchronization
Therapy was the first trial to show an improvement in HF, hospitaliza-
tion, and survival. Interestingly, while one large controlled study5 and
a meta-analysis of six trials8 showed a no reduction in mortality from
any cause in patients on RV pacing, with a HR of 1.14 (95% CI 0.81–
1.6) and 1.18 (0.26–5.22), respectively, a more recent large propen-
sity score-matched controlled study,12 in which 37% of patients had
received biventricular pacing and 63% RV pacing only, showed a
Figure 1 Trial flowchart.
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Table 1 Patient characteristics on enrolment
Abl1 CRT (n550) Drug (n552)
Age (years) 71 ± 12 72 ± 9
Male sex 28 (56) 28 (54)
Body mass index 27.5 ± 4.2 29.7 ± 7.7
Systolic blood pressure (mmHg) 124 ± 17 120 ± 14
History of AF
Duration of permanent AF (months) 13 (8–36) 18 (8–43)
Previous intermittent AF 23 (46) 23 (44)
Duration of intermittent AF (months) 24 (9–53) 18 (12–48)
Previous electrical cardioversion/s 18 (36) 21 (40)
Previous attempt/s at catheter ablation of AF 5 (10) 5 (10)
Number of hospitalizations for HF in the previous year 1.5 ± 0.7 1.7 ± 1.2
Symptoms and physical capacity
New York Heart Association class >_III 32 (64) 34 (65)
European Heart Rhythm Association class >_III 38 (76) 31 (60)
Specific symptoms of atrial fibrillation (SSS) (total score 0–60) 29.2 ± 31.0 29.6 ± 30.5
Palpitations (score 0–10) 4.7 ± 5.0 5.1 ± 3.7
Effort dyspnoea (shortness of breath during physical activity) (score 0–10) 7.4 ± 8.0 8.0 ± 1.7
Rest dyspnoea (shortness of breath at rest), (score 0–10) 3.5 ± 4.0 4.1 ± 3.1
Exercise intolerance (fatigue during mild physical activity) (score 0–10) 7.5 ± 8.0 7.6 ± 2.1
Easy fatigue at rest (score 0–10) 3.8 ± 4.0 3.6 ± 3.0
Chest discomfort (score 0–10) 2.3 ± 2.0 2.1 ± 2.5
Standard electrocardiogram on enrolment
Heart rate (b.p.m.) 100 ± 23 103 ± 19
QRS width (ms) 97 ± 14 94 ± 12
Echocardiogram
Left ventricular end-diastolic diameter (mm) 59 ± 12 56 ± 9
Left ventricular end-systolic diameter (mm) 44 ± 10 43 ± 11
Ejection fraction 41 ± 12 40 ± 12
Ejection fraction <_35% 20 (40) 23 (44)
Medical history
Hypertension 35 (70) 39 (75)
Diabetes 9 (18) 12 (23)
Coronary heart disease 13 (26) 19 (36)
Dilated cardiomyopathy 12 (24) 7 (13)
Valvular heart disease 11 (22) 7 (13)
Associated mitral valve disease 14 (28) 8 (15)
Stroke/transient ischaemic attack 6 (12) 4 (8)
Pulmonary diseases 8 (16) 9 (17)
Renal insufficiency 10 (20) 9 (17)
Medications (after optimization at 30 days)
Digoxin 18 (36)* 30 (58)*
Verapamil/diltiazem 6 (12) 6 (12)
Amiodarone/sotalol 1 (2) 3 (6)
Beta-blockers 42 (84) 43 (83)
Diuretics 46 (92) 48 (92)
Angiotensin-converting enzyme inhibitors or receptor blocker 34 (68) 28 (54)
Mineralocorticoid antagonist 25 (50) 27 (52)
Other vasodilators 10 (20) 16 (31)
Antiplatelets 8 (16) 11 (21)
Anticoagulants 47 (94) 48 (92)
Values are given as n (%) and continuous variables are given as mean ± SD or median (interquartile range) as appropriate.
*P= 0.03.
EF, ejection fraction; HF, heart failure.
AV junction ablation and CRT in AF patients 4003
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Table 2 Hazard ratio for the primary and secondary outcomes (intention-to-treat)
Outcomes Ablation1CRT
(n550)
Drug
(n5 52)
Hazard ratioa
(95% CI)
P-value
Combined endpoint of death due to HF, or
hospitalization for HF, or worsening HF, pts (%)
10 (20%) 20 (38%) 0.38 (0.18–0.81) 0.013
Combined endpoint and EF <_35%, pts (%) 3/21 (14%) 11/22 (50%) 0.18 (0.05–0.66) 0.010
Combined endpoint and EF >35%, pts (%) 7/29 (24%) 9/30 (30%) 0.62 (0.23–1.70) 0.359
Combined endpoint of death from any cause,
or hospitalization for HF
6 (12%) 17 (33%) 0.28 (0.11–0.72) 0.008
Death from any cause, pts (%) 2 (4%) 6 (12%) 0.30 (0.06–1.50) 0.147
Death due to HF 1 2
Death due to other causes or unknown 1 4
Hospitalizations for HF, pts (%) 5 (10%) 13 (25%) 0.30 (0.11–0.84) 0.024
Worsening HF, pts (%) 5 (10%) 8 (15%) 0.55 (0.18–1.68) 0.294
aHazard ratios were calculated by means of the Cox proportional hazard model.
EF, ejection fraction; HF, heart failure; pts, patients.
Take home figure The Kaplan–Meier curves comparing cumulative incidence of the primary and secondary endpoints in the two study groups.
(A) The cumulative incidence of the primary composite outcome of death due to heart failure, or hospitalization due to heart failure, or worsening
heart failure is shown. (B) The cumulative incidence of patients who died from heart failure or were hospitalized for heart failure is shown. (C) The
cumulative incidence of patients who died from any cause is shown. The event rates at one at 2 years of follow-up are shown (D) The cumulative inci-
dence of patients who were hospitalized for heart failure is shown..
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0.77)]. In the present study, in which all patients underwent biventric-
ular pacing, there was a trend toward an even greater reduction in
mortality, the HR being 0.30. While these findings suggest a correl-
ation between CRT and mortality reduction, the on-going larger
Mortality trial is warranted, in order to confirm this.
APAF-CRT enrolled patients with permanent AF, i.e. according to
the ESC guideline definition, ‘AF which is accepted by the patient
(and physician). Hence, rhythm-control interventions are no longer
pursued’.23 In the other cases, a rhythm-control strategy should be
pursued whenever possible.23 In the PABA-CHF trial,25 the investiga-
tors reported that, on 6 months follow-up examination, AF ablation
Figure 2 Subgroup analyses of the primary endpoint. Hazard ratio and P values for interaction are based on Cox logistic-regression analyses.
There was a significant interaction of the primary endpoint (death from heart failure, or hospitalization for heart failure, or worsening heart failure)
with ejection fraction and Specific Symptom Scale, which implies that patients with an ejection fraction <_35% and those with more symptomatic atrial
fibrillation (Specific Symptom Scale >31) are more likely to benefit from AV junction ablation and cardiac resynchronization therapy pacing.
.......................................................... .............................................................
....................................................................................................................................................................................................................
Table 3 Quality of life assessed by Specific Symptom Scale score at the baseline and at 1 year follow-up visit
(on-treatment analysis) in 50 patients who had effective Ablation1 CRTand in 42 patients on Drug therapy
SSS score Baseline 1 year visit
Ablation1CRT Drug Ablation1CRT Drug
SSS score, total (range 1–60) 29.6 ± 9.7 29.0 ± 9.0 10.5 ± 8.7 16.3 ± 11.2
Palpitations (range 1–10) 4.9 ± 3.7 5.3 ± 3.6 1.0 ± 1.4 3.3 ± 3.3
Effort dyspnoea (a) (range 1–10) 7.4 ± 2.0 7.5 ± 2.0 3.2 ± 2.5 4.3 ± 2.4
Rest dyspnoeaa 3.7 ± 2.8 3.8 ± 2.8 1.2 ± 1.6 1.9 ± 2.1
Effort intoleranceb 7.4 ± 1.9 7.0 ± 2.4 3.2 ± 2.3 4.3 ± 2.5
Easy fatigue 3.9 ± 3.0 3.2 ± 2.7 1.2 ± 1.6 1.5 ± 1.8
Chest discomfort 2.3 ± 2.6 2.1 ± 2.4 0.8 ± 1.3 1.1 ± 1.9
Values are given as n (%) and continuous variables are given as mean ± SD. Repeated measures ANOVA, treatment effect: F(1,90) = 8.60; P= 0.0043. The SSS score reduction
at the 1 year follow-up visit was greater in the AblationþCRT group.
aShortness of breath during physical activity.
bFatigue during mild physical activity.
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was superior to AV junction ablation combined with CRT with re-
gard to the composite Endpoint of EF, 6-min-walk test distance and
quality of life. Moreover, in the larger CASTLE trial,26 the use of abla-
tion for AF in patients with HF was associated with a significantly
lower rate of a composite of death from any cause and hospitalization
for HF than medical therapy, with a HR of 0.62 (95% CI 0.43–0.87). In
that study, however, stable sinus rhythm was difficult to achieve, des-
pite the association of antiarrhythmic drug therapy and repeated pro-
cedures in many patients; finally, 40% to 50% of patients failed to
maintain sinus rhythm over 60 months of follow-up. The persistence
of AF and the harmful effect of antiarrhythmic drug therapy in so
many patients in the CASTLE trial might explain why, in APAF-CRT,
we achieved an even greater reduction in the combined Endpoint of
death from any cause and hospitalization, with a HR of 0.26 (Table 2
and Take home figure). However, the two trials cannot be directly
compared, owing to major differences in baseline clinical characteris-
tics. For example, CASTLE patients were, on average, 8 years
younger, no patient was older than 71 years, 72% had intermittent AF
and 69% were in NYHA Class I or II.
In the APAF-CRT trial, the indication for CRT was primarily an in-
dication for AV junction ablation in order to achieve optimal rate
control. Narrow QRS (i.e. <120 ms) is a contraindication for CRT in
patients with sinus rhythm.15–17 Is AV junction ablation a prerequisite
for successful CRT even in AF patients with wide QRS who have con-
ventional indications for CRT, as suggested by some registries and
meta-analyses?27–30 In the absence of randomized trials, a substudy of
the RAFT trial31 was unable to show a benefit of CRT without AV
junction ablation with regard to the combined Endpoint of death and
hospitalization for HF (HR of 0.96). An on-going trial is specifically
addressing this issue (RAFT-PermanAF ClinicalTrials.gov Identifier:
NCT01994252, last update January 2016).
Limitations
Although the study was terminated in accordance with the pre-
specified rules, we acknowledge the risk of bias due to termination
upon interim analysis and to the small number of events in analysis.
Nevertheless, the robustness of the results is reinforced by the posi-
tive results of several sensitivity analyses (Supplementary material on-
line). On balance, the morbidity trial should be considered an
exploratory trial, the results of which need to be confirmed by the
on-going mortality trial.
One of the limitations of the APAF-CRT trial is the lack of blinding
with regard to randomization and treatment. Indeed, it would have
been quite difficult to perform a truly blinded trial involving a sham abla-
tion procedure. Admittedly, however, this lack of blinding could have
led to bias in the adjudication of events, especially with regard to the
softer Endpoint of worsening HF. This bias is common to most trials
performed on devices or interventions for HF and AF. The effect of this
potential bias was, however, mitigated by the fact that the outcomes
were adjudicated by an independent blind Clinical Events Committee.
Moreover, Drug arm patients with EF <35% also had a device (ICD)
implanted, which may have in some way balanced the expectation effect
driven by the interventional procedure in the active arm.
Although a greater number of patients in the Drug arm than in the
Ablation and CRT arm crossed over to the other treatment group,
the results of per-protocol and on-treatment analyses were similar
to those of the primary analysis (see Supplementary material online,
Figure S2).
The definition of permanent AF is highly subjective and is influ-
enced by several factors, including geographical/system differences in
the aggressiveness of rhythm-control strategies among centres. This
may affect the external validity of the study.
The benefit of ablation plus CRT was higher in patients with low
EF. For example, the HR of the composite of death from any cause,
or hospitalization from HF, or worsening HF was 0.18 (95% CI 0.05–
0.66) in patients with EF <_35%, 0.45 (95% CI 0.15–1.34) in patients
with EF 36–50% and 1.00 (95% CI 0.16–6.00) in patients with EF
>50%, thus suggesting no benefit in these latter patients. The
Biventricular vs. Right Ventricular Pacing in Heart Failure Patients
with Atrioventricular Block (BLOCK HF) trial32 showed a benefit of
CRT over RV pacing in patients with EF <_50%. Future studies should
address the benefit of CRT in patients with normal EF. Ejection frac-
tion value at follow-up would have been useful in correlating the clin-
ical outcome but it was not available being not required by the study
protocol.
Finally, this was a selected population of elderly patients recruited
from among those referred to a cardiology department, and not
from among the total populations of patients hospitalized for HF; our
patients might therefore not be fully representative of the general
population of patients hospitalized for HF.
Conclusion and perspectives
In conclusion, the results of the APAF-CRT Morbidity trial show that
the strategy of AV junction ablation and CRT is both safe and super-
ior to conventional medical strategy in relieving symptoms of HF and
reducing hospitalization for HF in elderly patients affected by per-
manent AF and narrow QRS. Compared with drug therapy, AV junc-
tion ablation and CRT yielded an absolute risk reduction of 18% in
the composite primary outcome, with a number needed to treat of
5.5; this result was largely driven by the reduction in hospitalizations
Figure 3 Symptoms and physical limitations assessed by Specific
Symptom Scale score, at the baseline and at 1 year follow-up visit.
On-treatment analysis in patients with ejection fraction <_35% and
in those with ejection fraction >35%. Mean values and 95% confi-
dence interval are reported. EF, ejection fraction; SSS, specific symp-
tom scale.
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..for HF. Such interventional therapy should be offered to patients
with symptomatic HF refractory to pharmacological therapy who
cannot undergo catheter ablation of AF for the maintenance of sinus
rhythm, or in whom ablation has failed. While AF-related symptoms
are expected to improve more in patients with preserved EF, the re-
duction in harder endpoints is expected to be more marked in those
with reduced EF. Although the Morbidity trial was not sized to assess
mortality, the observed trend in reduction in death from any cause
justifies the ongoing Mortality trial.
Supplementary material
Supplementary material is available at European Heart Journal online.
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